Introduction The PHOTON Phase 2/3 trial demonstrated the efficacy and safety of intravitreal aflibercept 8 mg in the treatment of diabetic macular oedema (DME) [1]. SPECTRUM is a global study evaluating aflibercept 8 mg treatment of DME and neovascular age-related macular degeneration (nAMD) in routine clinical practice. This SPECTRUM analysis presents early clinical experience with aflibercept 8 mg among patients with treatment-naïve (TN) or previously treated (PT) DME.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile